Publications
Below is a list of publications resulting from RTOG Foundation clinical trials.
List of Publications
Study |
Type |
Year |
Citation |
|||
| RTOG 3504 | Manuscript | 2022 | Gillison ML, Ferris RL, Harris J, Colevas AD, Mell LK, Kong C, Jordan RC, Moore KL, Truong MT, Kirsch C, Chakravarti A, Blakaj DM, Clump DA, Ohr JP, Deeken JF, Gensheimer MF, Saba NF, Dorth JA, Rosenthal DI, Leidner RS, Kimple RJ, Machtay M, Curran WJ Jr, Torres-Saavedra P, Le QT. Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504. Int J Radiat Oncol Biol Phys. 2022 Oct 10:S0360-3016(22)03434-4. doi: 10.1016/j.ijrobp.2022.10.008. Epub ahead of print. PMID: 36228746. https://pubmed.ncbi.nlm.nih.gov/36228746/ |
|||
| RTOG 3508 | Manuscript | 2022 | Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, Ansell PJ, Samanta S, Kundu MG, Armstrong TS, Wefel JS, Seidel C, de Vos FY, Hsu S, Cardona AF, Lombardi G, Bentsion D, Peterson RA, Gedye C, Bourg V, Wick A, Curran WJ, Mehta MP. Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 2022 Jul 15:noac173. doi: 10.1093/neuonc/noac173. Epub ahead of print. PMID: 35849035. | |||
| RTOG 3505 | Manuscript | 2017 | Gerber DE, Urbanic JJ, Langer C, Hu C, Chang IF, Lu B, Movsas B, Jeraj R, Curran WJ, Bradley JD. Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small-cell lung cancer (RTOG 3505). Clin Lung Cancer. 2017;18(3):333-339. doi:10.1016/j.cllc.2016.10.009 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406261/ | |||
| RTOG 3508 | Abstract | 2019 | Lassman A, Pugh S, Wang T, Aldape K, Gan H, Preusser M, Vogelbaum M, Sulman E, Won M, Zhang P, Moazami G, Macsai M, Gilbert M, Bain E, Blot V, Ansell P, Samanta S, Kundu M, Seidel C, De Vos F, Hsu S, Cardona A, Lombardi G, Bentsion D, Peterson R, Gedye C, Lebrun-Frénay C, Wick A, Curran W, Mehta M. ACTR-21. randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in epidermal growth factor receptor (EGFR) amplified (AMP) newly diagnosed glioblastoma (nGBM). Neuro Oncol . 2019;21(Suppl 6):vi17. doi:10.1093/neuonc/noz175.064 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6847524/ | |||
| RTOG 3508 | Manuscript | 2019 | Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. J Neurooncol . 2019;144(1):205-210. doi:10.1007/s11060-019-03222-y https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082754/ |